Why ScanScor Focuses on the Biotech Sector

ScanScor was designed to predict the future. To do that well, we needed to focus on the one sector of the market where breakouts happen frequently, dramatically, and for real reasons: biotech.

Biotech Offers a Unique Advantage

Biotech companies regularly undergo major breakthroughs — or setbacks — based on scientific results. These outcomes are tied to scheduled events like clinical trials and FDA reviews, giving us real catalysts to analyze in advance. Compare that to other sectors like fintech, energy, or consumer products — where price movement is vague, sentiment-driven, or tied to macro news. In biotech, moves are driven by **trial phases, approvals, and data**. And that’s exactly what our AI looks for.

Our Main Reason: FDA and Study Trials

Unlike any other industry, biotech is structured around a regulatory framework — the FDA — and a constant stream of trial data. These events are trackable, predictable, and often explosive. This is what gives biotech an edge for AI-powered forecasting.

The Breakouts Are Bigger

Biotech doesn’t just move — it launches. While most industries are lucky to see a 10–20% spike, biotech regularly delivers 60%, 120%, even 300%+ moves within a matter of days. These aren’t hype-driven; they’re the result of verified scientific progress or regulatory news.

Biotech Has the Most Tickers That Matter

There are over 800 biotech companies trading on U.S. exchanges, many under $10 with active pipelines. It is by far the most event-rich, catalyst-heavy, and breakout-prone sector in the entire market.

Retail Investors Are Often Afraid of It — And That’s Our Edge

Biotech is filled with complex terminology, misunderstood risks, and obscure data. Retail investors often skip it entirely. That’s where ScanScor steps in — we read the filings, decode the trials, and summarize the opportunity in plain English. Our AI is trained to cut through the noise.

Orbo’s Not a Stock Picker — He’s a ✨Time ✨Machine✨

Our goal isn’t just to identify promising stocks — it’s to forecast the moment when attention, science, and price collide. Biotech is the only sector where the future reveals itself in scheduled events, and ScanScor was born to predict them.

This Is Just the Beginning

We may expand to other sectors one day, but for now, we’re exactly where we want to be: in the high-stakes, high-potential world of biotech. It’s fast. It’s fascinating. And it’s filled with signals just waiting to be decoded. That’s why we chose biotech. And why we’re staying here — until the whole world sees what we already do.

What’s Next?

We’re currently preparing an update to our AI predictions, focusing on new breakout windows expected to open during the month of August. Several of our original predictions will be replaced with fresh outlooks based on the latest data and upcoming catalysts. Stay tuned for the updated prediction set — and watch these tickers closely.